Zrinka Kovarik

1. Introduction The current therapy for acute exposure to organophosphates (OPs) consists of a combination of active substances that includes an anticholinergic, a cholinesterase reactivator, and an anticonvulsant [1,2]. Oximes, reactivators of the enzyme acetylcholinesterase (AChE), possess a C=N-OH group that, upon a nucleophilic attack on the electrophilic phosphorus atom, breaks the bond between phosphorus and the catalytic serine of AChE, resulting in a free enzyme and a phosphorylated oxime.

Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 11 May 2024 / Approved: 13 May 2024 / Online: 13 May 2024 (14:38:38 CEST) Mlakić, M.; Čadež, T.; Šinko, G.; Škorić, I.; Kovarik, Z. New Heterostilbene and Triazole Oximes as Potential CNS-Active and Cholinesterase-Targeted Therapeutics. Preprints 2024, 2024050883. https://doi.org/10.20944/preprints202405.0883.v1 Mlakić, M.; Čadež, T.; Šinko, G.; Škorić, I.; Kovarik, Z.

CONFLICT OF INTEREST STATEMENT ZK is an associate editor for the Biofactors. REFERENCES 1, . Counteracting poisoning with chemical warfare nerve agents. Arh Hig Rada Toksikol. 2020; 71(4): 266–284. 2. Organophosphorus compounds at 80: some old and new issues. Toxicol Sci. 2018; 162(1): 24–35. 3, , , , , , et al. Advice on assistance and protection provided by the Scientific Advisory Board of the Organisation for the prohibition of chemical weapons: part 1.